Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Obese women with history of gestational diabetes are in great danger to develop type 2
diabetes (T2D) within 5-10 years after delivery. Aim of the study is to investigate if 12
months' liraglutide treatment could decrease the risk of T2D in obese women who have had
gestational diabetes. The women are randomized either to liraglutide (Victoza ® 1.8 mg) or
placebo group, once daily. Same laboratory tests are taken and instructions given at baseline
6 month and one year. After one year visits once a year until 5 years with same laboratory
tests and measurements are taken.